News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Lorus Therapeutics Inc. (LRP) Reports First Quarter Results for Fiscal Year 2011

10/15/2010 8:58:07 AM

TORONTO, ONTARIO--(Marketwire - October 15, 2010) - Lorus Therapeutics Inc. (TSX: LOR)(OTCBB: LRUSF) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today reported financial results for the three months ended August 31, 2010.

Q1 2011 HIGHLIGHTS                                                          

--  Received approval of the Investigational New Drug ("IND") application
    for Lorus' anticancer drug candidate LOR-253 by the U.S. FDA. Based on
    the approval of the IND by the FDA, Lorus plans to proceed with a first-
    in-man Phase I dose escalation trial with LOR-253 in advanced or
    metastatic solid tumors. The trial will assess the safety profile,
    tolerability, and antitumor activity of LOR-253 in cancer patients. It
    is expected that the Phase I trial will be initiated by the end of the
    calendar year. 

--  Filed a final short form prospectus for units of the Corporation (the
    "Rights Offering"). Under the Rights Offering, holders of common shares
    of the Corporation as of October 12, 2010 (the "Record Date") will
    receive one right for each common share held as of the Record Date. Each
    two (2) rights will entitle the holder thereof to purchase a unit of the
    Corporation ("Unit") at a price of $1.11 per Unit. Each Unit consists of
    one common share of the Corporation and one warrant to purchase an
    additional common share of the Corporation at a price of $1.33 until May
    2012. The Corporation has secured a standby purchase arrangement by
    Herbert Abramson, one of Lorus' directors whereby Mr. Abramson will make
    an investment such that the minimum gross proceeds of the Rights
    Offering are $4 million. There will be no fee paid to Mr. Abramson for
    this commitment. Mr. Abramson is also providing the Company with interim
    financing by way of three $500 thousand monthly loans, all have been
    advanced as of October 5, 2010. The loans are unsecured, have a six-
    month term (or the earlier of the closing of the Rights Offering) and
    bear interest at the annual rate of 10%. These loans will be repaid from
    the proceeds of the rights offering. 

--  Announced the publication of a peer-reviewed scientific article
    describing synthesis and antibacterial activity of novel antimicrobial
    compounds from Lorus' small molecule program. The article reported the
    results of studies showing that many of these compounds exhibited potent
    growth inhibition of multidrug resistant bacterial strains. Some of the
    compounds showed comparable antibacterial activity to that of vancomycin
    and higher activity than linezoid, both of which are antibiotics
    currently used to treat serious bacterial infections. 


Our loss from operations for the three months ended August 31, 2010 was $1.2 million ($0.12 per share) compared with $1.2 million ($0.15 per share) during the same period in fiscal 2010. During the three months ended August 31, 2009 the Company recorded a gain on the repurchase of its secured convertible debentures of $11.0 million reflecting the difference between the fair value of the debentures at the repurchase date, net of transaction costs of $221 thousand, and the cash payment amount of $3.3 million resulting in net income for the period of $9.8 million (income $1.14 per share).

Loss from operations for the three months ended August 31, 2010 compared with the same period in the prior year remained consistent. Lower research and development expenditures of $51 thousand due to reduction in spending to conserve cash, lower stock based compensation expense of $56 thousand due to no stock options issued in the first quarter of 2011 as well as no accretion in the carrying value of the convertible debentures due to their settlement in the first quarter of 2010 were offset by no revenue in the current quarter compared with $49 thousand in the prior year as well as higher general and administrative spending of $56 thousand resulting from financing fees of $95 thousand due to the terminated US financing.

We utilized cash of $685 thousand in our operating activities in the three months ended August 31, 2010 compared with $987 thousand in the same period in the prior year. The decrease is primarily a result of increased current liabilities balances.

At August 31, 2010, we had cash and cash equivalents and short-term investments of $227 thousand compared to $914 thousand at May 31, 2010.

Research and development expenses totaled $489 thousand in the three months ended August 31, 2010 compared to $540 thousand during the same period in the prior year. The slight decrease in spending during the current period compared with the prior-year period is due to a reduction in expenditures during the current period in an effort to conserve cash. Costs incurred during the quarter related primarily to the preparation of the LOR-253 Phase I clinical trial to be initiated in the fourth quarter of calendar 2010.

General and administrative expenses totaled $589 thousand for the three months ended August 31, 2010 compared to $533 thousand in the same period in the prior year. The slight increase in costs is due to $95 thousand in financing fees related to the proposed US financing terminated during the quarter. Excluding these one time costs general and administrative costs were lower than the prior year, primarily due to headcount reductions.

Management has forecasted that the Company's current level of cash, cash equivalents and short-term investments is not sufficient to execute its current planned expenditures for the next twelve months without further investment. The Company is currently in discussion with several potential investors to provide additional funding. Management believes that it will complete one or more of these arrangements in sufficient time to continue to execute its planned expenditures without interruption. However, there can be no assurance that the capital will be available as necessary to meet these continuing expenditures, or if the capital is available, that it will be on terms acceptable to the Company.

Lorus Therapeutics Inc.                                                     
Consolidated Statements of (Loss) Earnings - Unaudited                      

(amounts in 000's except for per common      Three months      Three months 
 share data)                                        ended             ended 
(Canadian dollars)                          Aug. 31, 2010     Aug. 31, 2009 
REVENUE                                   $             -   $            49 

Research and development                              489               540 
General and administrative                            589               533 
Stock-based compensation                               49               105 
Depreciation and amortization of fixed                                      
 assets                                                14                21 
Operating expenses                                  1,141             1,199 
Interest expense                                       28                27 
Accretion in carrying value of convertible                                  
 debentures                                             -                80 
Interest income                                        (4)              (11)
Loss from operations for the period                (1,165)           (1,246)
Gain on repurchase of convertible                                           
 debentures and transfer of assets                      -            11,006 
Net (loss) earnings and other                                               
 comprehensive income for the period               (1,165)            9,760 
Basic and diluted (loss) earnings per                                       
 common share                             $         (0.12)  $          1.14 

Weighted average number of common shares                                    
 outstanding used in the calculation of                                     
 Basic and Diluted (loss) earnings per                                      
 common share                                       9,933             8,567 

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR and the Over the Counter Bulletin Board under the symbol LRUSF.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the completion of the rights offering, future financing, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward-looking statements could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; our ability to complete the proposed rights offering; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Lorus Therapeutics Inc.'s recent press releases are available through its website at For Lorus' regulatory filings on SEDAR, please go to

Lorus Therapeutics Inc.
Elizabeth Williams
Director of Finance
1-416-798-1200 ext. 372

Read at

comments powered by Disqus